MONTREAL, June 9, 2022
/CNW/ - Lumiera Health Inc. (TSXV: NHP) (the
"Company" or "Lumiera "), a company specializing
in the development and commercialization of natural health
products, is pleased to announce the launch of its Awaye™ pain
relief cream in the US market. The first shipment of
Awaye™ has been sent to Amazon.com's distribution center and
will soon be available to American consumers.
"This is a major step forward for Lumiera; our first shipment to
the US and the first step to introducing Awaye™ to millions of
American that suffer with pain. The US pain relief market was
estimated at $2.5 billion dollars in
2020 and is forecasted to grow at a +9% CAGR" says Carlos Ponce, CEO of Lumiera. "Awaye™ has
seen great results on Amazon in Canada and we are very excited to announce our
first shipment to Amazon in the US. As previously shared, we
are receiving incredibly positive feedback from consumers across
Canada that have found relief with
Awaye™ and we are now ready to start introducing Awaye™ to
Americans that are looking for safe, natural solutions to manage
their pain. I look forward to sharing updates on our progress on
Amazon.com as well as our pending retail distribution in the
Northeast US as we continue to execute on our US distribution
strategy."
About Awaye™
Awaye™ provides a new generation of relief from acute and
chronic pain by exploiting the CB2 receptors of the endocannabinoid
system, the body's built-in pain and inflammation defense system.
Awaye™ is a unique Health Canada approved topical cream that
provides relief from pain through complimentary mechanisms of
action not found in any other product currently available on the
market.
For more information about Awaye™ products, visit
www.awaye.ca
About Lumiera Health
Lumiera specializes in the development and commercialization of
consumer products for the natural health industry. The Company
sells herbal tonics and natural supplements through its Holizen
Laboratories division, with a diverse portfolio including a line of
innovative sleep aids. The Company is also commercializing a unique
topical product line acting on the endocannabinoid system, without
the use of cannabis, that provides an innovative solution for
chronic pain and inflammation. A pioneer in the natural health
innovation space, the Lumiera brand is rooted in the core values of
science, nature and compassion. Our goal is to make people's
lives better by developing natural health and wellness products
that are effective, safe and trustworthy.
For more information visit: www.lumiera.ca.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Forward-looking information
Certain statements contained in this press release constitute
"forward-looking information" as such term is defined in applicable
Canadian securities legislation. The words "may", "would", "could",
"should", "potential", "will", "seek", "intend", "plan",
"anticipate", "believe", "estimate", "expect" and similar
expressions indicate such "forward-looking
information" as they relate to Lumiera. All statements other
than statements of historical fact may be forward-looking
information. Such statements reflect Lumiera' current views and
intentions with respect to future events, and current information
available to Lumiera, and are subject to certain risks,
uncertainties and assumptions. Such risks and uncertainties
include, among others, the risk factors included in Lumiera' annual
management's discussion and analysis for the year
ended November 30, 2021,
which is available under the issuer's SEDAR profile
at www.sedar.com. Material factors or assumptions
were applied in providing forward-looking information. Many factors
could cause the actual results, performance or achievements that
may be expressed or implied by such forward-looking information to
vary from those described herein should one or more of these risks
or uncertainties materialize. Should any factor affect Lumiera in
an unexpected manner, or should assumptions underlying the
forward-looking information prove incorrect, the actual results or
events may differ materially from the results or events predicted.
Any such forward-looking information is expressly qualified in its
entirety by this cautionary statement. Moreover, Lumiera does not
assume responsibility for the accuracy or completeness of such
forward-looking information. The forward-looking information
included in this press release is made as of the date of this press
release and Lumiera undertakes no obligation to publicly update or
revise any forward-looking information, other than as required by
applicable law.
Related Links: www.lumiera.ca
SOURCE Lumiera Health Inc.